These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 16651204)

  • 1. Sexual functioning and satisfaction in nonresponders to testosterone gel: Potential effectiveness of retreatment in hypogonadal males.
    Steidle C; Witt MA; Matrisciano J; Block JE
    Clin Cornerstone; 2005; 7 Suppl 4():S20-5. PubMed ID: 16651204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Improvement in sexual functioning and satisfaction in nonresponders to testosterone gel: clinical effectiveness in hypogonadal, HIV-positive males.
    Schrader S; Mills A; Scheperle M; Block JE
    Clin Cornerstone; 2005; 7 Suppl 4():S26-31. PubMed ID: 16651205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
    McNicholas TA; Dean JD; Mulder H; Carnegie C; Jones NA
    BJU Int; 2003 Jan; 91(1):69-74. PubMed ID: 12614254
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimal diagnostic measures and thresholds for hypogonadism in men with HIV/AIDS: comparison between 2 transdermal testosterone replacement therapy gels.
    Blick G
    Postgrad Med; 2013 Mar; 125(2):30-9. PubMed ID: 23816769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Grober ED; Khera M; Soni SD; Espinoza MG; Lipshultz LI
    Int J Impot Res; 2008; 20(2):213-7. PubMed ID: 17898800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Review of Testim gel.
    McNicholas T; Ong T
    Expert Opin Pharmacother; 2006 Mar; 7(4):477-84. PubMed ID: 16503819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Testosterone Solution 2% on Ejaculatory Dysfunction in Hypogonadal Men.
    Maggi M; Heiselman D; Knorr J; Iyengar S; Paduch DA; Donatucci CF
    J Sex Med; 2016 Aug; 13(8):1220-6. PubMed ID: 27436077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testim 1% testosterone gel for the treatment of male hypogonadism.
    Bouloux P
    Clin Ther; 2005 Mar; 27(3):286-98. PubMed ID: 15878382
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved sexual function with testosterone replacement therapy in hypogonadal men: real-world data from the Testim Registry in the United States (TRiUS).
    Khera M; Bhattacharya RK; Blick G; Kushner H; Nguyen D; Miner MM
    J Sex Med; 2011 Nov; 8(11):3204-13. PubMed ID: 21834870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Effect of Testosterone Topical Solution in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel.
    Burns PR; Kim ED; Ruff DD; Seftel AD
    Am J Mens Health; 2018 May; 12(3):524-530. PubMed ID: 26438471
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Absorption of testosterone gel 1% (Testim) from three different application sites.
    Guay AT; Smith TM; Offutt LA
    J Sex Med; 2009 Sep; 6(9):2601-10. PubMed ID: 19549089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rationale, design and methods of the ESPRIT study: Energy, Sexual desire and body PropoRtions wIth AndroGel, Testosterone 1% gel therapy, in hypogonadal men.
    Behre HM; Heinemann L; Morales A; Pexman-Fieth C
    Aging Male; 2008 Jun; 11(2):101-6. PubMed ID: 18570063
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men.
    Wang C; Cunningham G; Dobs A; Iranmanesh A; Matsumoto AM; Snyder PJ; Weber T; Berman N; Hull L; Swerdloff RS
    J Clin Endocrinol Metab; 2004 May; 89(5):2085-98. PubMed ID: 15126525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Restorative increases in serum testosterone levels are significantly correlated to improvements in sexual functioning.
    Seftel AD; Mack RJ; Secrest AR; Smith TM
    J Androl; 2004; 25(6):963-72. PubMed ID: 15477371
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transdermal androgen therapy to augment EPO in the treatment of anemia of chronic renal disease.
    Brockenbrough AT; Dittrich MO; Page ST; Smith T; Stivelman JC; Bremner WJ
    Am J Kidney Dis; 2006 Feb; 47(2):251-62. PubMed ID: 16431254
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Response to: Efficacy of changing testosterone gel preparations (Androgel or Testim) among suboptimally responsive hypogonadal men.
    Morgentaler A
    Int J Impot Res; 2008; 20(3):331; author reply 332. PubMed ID: 18475269
    [No Abstract]   [Full Text] [Related]  

  • 17. A 6-month observational study of energy, sexual desire, and body proportions in hypogonadal men treated with a testosterone 1% gel.
    Pexman-Fieth C; Behre HM; Morales A; Kan-Dobrosky N; Miller MG
    Aging Male; 2014 Mar; 17(1):1-11. PubMed ID: 24274081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 9-Month Efficacy and Safety Study of Testosterone Solution 2% for Sex Drive and Energy in Hypogonadal Men.
    Brock G; Heiselman D; Knorr J; Ni X; Kinchen K
    J Urol; 2016 Nov; 196(5):1509-1515. PubMed ID: 27117440
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function.
    Blacklock AR
    BJU Int; 2003 Sep; 92(4):490. PubMed ID: 12930448
    [No Abstract]   [Full Text] [Related]  

  • 20. Subjective sexual response to testosterone replacement therapy based on initial serum levels of total testosterone.
    Reyes-Vallejo L; Lazarou S; Morgentaler A
    J Sex Med; 2007 Nov; 4(6):1757-62. PubMed ID: 17087806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.